deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02272413

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin® Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

Sponsor: Boehringer Ingelheim

Conditions Carcinoma, Non-Small-Cell Lung
Interventions Avastin BI 695502
Updated 21 times since 2017 Last updated: Dec 26, 2019 Started: Jul 8, 2015 Primary completion: Jun 30, 2017 Completion: Nov 16, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Carcinoma, Non-Small-Cell Lung and is currently completed. Boehringer Ingelheim leads this study, which shows 21 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Feb 2020 · 14 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 16 earlier versions

  1. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE3

  2. Dec 2018 — Feb 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Oct 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2018 — Apr 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2018 — Feb 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Oct 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Sep 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE3

  12. Jun 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  13. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  14. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  15. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Nagakute, Japan , Aichi, Okazaki, Japan , Aichi, Seto, Japan , Aichi, Toyoake, Japan , Al Mansurah, Egypt , Alexandria, Egypt , Anaheim, United States , Antalya, Turkey (Türkiye) , Arkhangelsk, Russia , Ashland, United States and 147 more locations